PALISADE BIO, INC.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PALI$1.13-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
nts of Cash Flows (Unaudited)
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Net loss | $(34,797) | $(7,882) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | — | 3 |
| Non-cash operating lease expense | — | 84 |
| Recurring fair value measurements of liabilities | 1 | 323 |
| Write-off of deferred equity issuance costs | — | 75 |
| Stock-based compensation and related charges | 14,147 | 228 |
| Other | — | (61) |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets and other noncurrent assets | (4,223) | (537) |
| Accounts payable and accrued liabilities | 2,145 | 255 |
| Accrued compensation and benefits | (525) | (101) |
| Operating lease liabilities | — | (90) |
| Net cash used in operating activities | (23,252) | (7,703) |
| Cash flows from financing activities: | ||
| Payments on insurance financing debt | (71) | (180) |
| Proceeds from issuance of common stock | 3,450 | — |
| Proceeds from the exercise of warrants | 155 | 3,909 |
| Payment of warrant inducement issuance costs | — | (445) |
| Payment of equity issuance costs | (74) | (178) |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 20 | 3 |
| Net cash provided by financing activities | 3,480 | 3,109 |
| Net decrease in cash, cash equivalents and restricted cash | (19,772) | (4,594) |
| Cash, cash equivalents and restricted cash, beginning of year | 133,440 | 9,847 |
| Cash, cash equivalents and restricted cash, end of period | $113,668 | $5,253 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: | ||
| Cash and cash equivalents | $113,613 | $5,227 |
| Restricted cash | 55 | 26 |
| Total cash, cash equivalents and restricted cash | $113,668 | $5,253 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $1 | $5 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Warrant inducement costs included in accounts payable and accrued liabilities | $— | $50 |
| Payment of equity issuance costs previously included in accounts payable and accrued liabilities | 46 | — |
| Fair value of common shares issued in settlement of share liability (Note 4) | 313 | — |
| Fair value of common shares issued in settlement of derivative liability (Note 4) | 50 | — |
| Fair value of warrants issued to solicitation agent in warrant inducements (Note 5) | — | 233 |
| Insurance financing debt included in prepaid and other current assets and other noncurrent assets | — | 312 |
| Incremental fair value of modified warrants (Note 5) | — | 8,602 |
PALISADE BIO, INC.
NOTES TO CONDENSED CONSO
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.